SG11202100983XA - Method of producing tetracyclic compound - Google Patents

Method of producing tetracyclic compound

Info

Publication number
SG11202100983XA
SG11202100983XA SG11202100983XA SG11202100983XA SG11202100983XA SG 11202100983X A SG11202100983X A SG 11202100983XA SG 11202100983X A SG11202100983X A SG 11202100983XA SG 11202100983X A SG11202100983X A SG 11202100983XA SG 11202100983X A SG11202100983X A SG 11202100983XA
Authority
SG
Singapore
Prior art keywords
tetracyclic compound
producing
producing tetracyclic
compound
tetracyclic
Prior art date
Application number
SG11202100983XA
Inventor
Hiroki Serizawa
Akira Kawase
Hiroshi Fukuda
Naoto HAMA
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG11202100983XA publication Critical patent/SG11202100983XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00Other general methods

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11202100983XA 2018-09-04 2019-09-03 Method of producing tetracyclic compound SG11202100983XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018165313 2018-09-04
PCT/JP2019/034543 WO2020050241A1 (en) 2018-09-04 2019-09-03 Method of producing tetracyclic compound

Publications (1)

Publication Number Publication Date
SG11202100983XA true SG11202100983XA (en) 2021-03-30

Family

ID=69722303

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100983XA SG11202100983XA (en) 2018-09-04 2019-09-03 Method of producing tetracyclic compound

Country Status (14)

Country Link
US (1) US11939322B2 (en)
EP (1) EP3848361A4 (en)
JP (1) JP7167171B2 (en)
KR (1) KR102635225B1 (en)
CN (1) CN112585126B (en)
AR (1) AR116113A1 (en)
AU (1) AU2019337018B2 (en)
BR (1) BR112021001145A2 (en)
CA (1) CA3107270A1 (en)
IL (1) IL281079B1 (en)
MX (1) MX2021002311A (en)
SG (1) SG11202100983XA (en)
TW (1) TWI825163B (en)
WO (1) WO2020050241A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023008735A (en) 2021-01-29 2023-08-01 Chugai Pharmaceutical Co Ltd Drug composition for treating pediatric cancers.

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS506987B1 (en) 1970-02-17 1975-03-19
JPS4918630B1 (en) 1970-07-29 1974-05-11
JPS5859712U (en) 1981-10-16 1983-04-22 ニチバン株式会社 label pasting machine
JPH0892090A (en) 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd Medicinal composition
DE69505470T2 (en) 1994-08-04 1999-05-12 F. Hoffmann-La Roche Ag, Basel Pyrrolocarbazole
IL126762A0 (en) 1996-05-01 1999-08-17 Lilly Co Eli Halo-substituted protein kinase c inhibitors
RU2238937C2 (en) 1998-12-24 2004-10-27 Фудзисава Фармасьютикал Ко., Лтд. Derivatives of imidazole, pharmaceutical composition and method for prophylaxis and/or treatment based on thereof
JP2002544275A (en) 1999-05-14 2002-12-24 ジ・オーストラリアン・ナショナル・ユニバーシティー Compounds and methods of treatment
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
FR2841138B1 (en) 2002-06-25 2005-02-25 Cll Pharma SOLID PHARMACEUTICAL COMPOSITION COMPRISING A LIPOPHILIC ACTIVE INGREDIENT, ITS PREPARATION PROCESS
AU2004258801A1 (en) 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
PT1454992E (en) 2003-03-07 2006-09-29 Ist Naz Stud Cura Dei Tumori KINASE-TEST OF ANAPLASTIC LYMPHOMA, REAGENTS AND COMPOSITIONS
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4836788B2 (en) 2003-07-23 2011-12-14 エグゼリクシス, インコーポレイテッド Undifferentiated lymphoma kinase modulators and methods of use thereof
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
MXPA06005702A (en) 2003-11-21 2006-08-17 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors.
CN100548986C (en) 2003-12-12 2009-10-14 默克弗罗斯特加拿大有限公司 Cathepsin cysteine protease inhibitors
US7868036B2 (en) 2004-03-19 2011-01-11 Novartis Ag Organic compounds
US20090155903A1 (en) 2004-03-19 2009-06-18 Myriad Genetics, Incorporated Pharmaceutical composition and method
AU2005230847B2 (en) 2004-03-31 2012-11-08 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
WO2005121102A2 (en) 2004-06-02 2005-12-22 Pharmacyclics, Inc. Factor viia inhibitor
RS51362B (en) 2004-08-26 2011-02-28 Pfizer Inc. Enantiomerically pure aminoheteroaryl compunds as protein kinase inhibitors
US7091202B2 (en) 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
KR20080056288A (en) 2005-11-07 2008-06-20 아이알엠 엘엘씨 Compounds and compositions as ppar modulators
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
MX2009004426A (en) 2006-10-23 2009-08-12 Cephalon Inc Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors.
CN101687873A (en) 2007-04-17 2010-03-31 百时美施贵宝公司 11 beta-hydroxysteroid dehydrogenase type i inhibitors with annelated heterocycles
TWI389893B (en) 2007-07-06 2013-03-21 Astellas Pharma Inc Di (arylamino) ary1 compound
EP2176231B1 (en) 2007-07-20 2016-10-19 Nerviano Medical Sciences S.r.l. Substituted indazole derivatives active as kinase inhibitors
JP5583592B2 (en) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション IDO inhibitor
WO2009113420A1 (en) 2008-03-13 2009-09-17 第一三共株式会社 Improvement of dissolvability of preparation containing olmesartan medoxomil
CN102574830A (en) 2009-05-07 2012-07-11 阿斯利康(瑞典)有限公司 Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
AR077025A1 (en) 2009-06-10 2011-07-27 Chugai Pharmaceutical Co Ltd TETRACICLIC COMPOUNDS
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
TWI526441B (en) 2010-08-20 2016-03-21 中外製藥股份有限公司 Composition comprising tetracyclic compounds
JP5006987B2 (en) 2010-11-22 2012-08-22 中外製薬株式会社 Medicine containing tetracyclic compound
AU2013321235B2 (en) 2012-09-25 2017-07-20 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
CN113416179A (en) 2014-04-25 2021-09-21 中外制药株式会社 Novel crystal of tetracyclic compound
MX2016013809A (en) 2014-04-25 2017-03-09 Chugai Pharmaceutical Co Ltd Preparation containing tetracyclic compound at high dose.
CA2942186C (en) 2014-06-18 2023-06-27 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising non-ionic surfactants
TWI718102B (en) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 Amorphous body of tetracyclic compound
CN104402862B (en) * 2014-11-12 2016-10-05 苏州明锐医药科技有限公司 Ai Li is for the preparation method of Buddhist nun
US9573932B2 (en) 2015-03-02 2017-02-21 Yong Xu Synthesis of intermediates in the preparation of ALK inhibitor
WO2017073706A1 (en) 2015-10-30 2017-05-04 中外製薬株式会社 DIHYDRONAPHTHO[2,3-b]BENZOFURAN DERIVATIVE
CN107033124B (en) 2017-04-21 2019-09-20 湖南博奥德药业有限公司 A kind of Ai Le replaces the preparation method of Buddhist nun
CN106928185B (en) 2017-04-21 2019-09-20 湖南博奥德药业有限公司 A kind of Ai Le replaces the preparation method of Buddhist nun
CN106928184B (en) 2017-04-21 2019-09-20 湖南博奥德药业有限公司 A kind of Ai Le replaces the preparation method of Buddhist nun

Also Published As

Publication number Publication date
JPWO2020050241A1 (en) 2021-08-30
US11939322B2 (en) 2024-03-26
BR112021001145A2 (en) 2021-04-20
AU2019337018B2 (en) 2024-03-07
WO2020050241A1 (en) 2020-03-12
EP3848361A1 (en) 2021-07-14
TWI825163B (en) 2023-12-11
TW202024050A (en) 2020-07-01
CA3107270A1 (en) 2020-03-12
KR102635225B1 (en) 2024-02-07
IL281079B1 (en) 2024-08-01
JP7167171B2 (en) 2022-11-08
AR116113A1 (en) 2021-03-31
CN112585126A (en) 2021-03-30
EP3848361A4 (en) 2022-06-15
CN112585126B (en) 2024-05-07
KR20210053890A (en) 2021-05-12
US20220372025A1 (en) 2022-11-24
MX2021002311A (en) 2021-04-28
IL281079A (en) 2021-04-29
AU2019337018A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
IL269651A (en) Improved method of producing collagenase
HUE057666T2 (en) Method for preparing intermediate of 4-methoxypyrrole derivative
GB201806072D0 (en) Methods of manufacture
SG11202103664WA (en) Process for producing perfluoroalkyne compound
GB201804594D0 (en) Bonegraft substituteand method of manufacture
PL3755681T3 (en) Method of 4-boronophenylalanine production
PL3733651T3 (en) Method for producing calcobutrol
IL287063A (en) Method for producing biotissue-like structure
IL281431A (en) Methods of producing pyrazole compounds
EP3257834A4 (en) Method of producing c2-c4 carbonyl compounds
EP3643701A4 (en) Method for producing compound
GB201802839D0 (en) Method of manufacture
GB201805904D0 (en) Methods of Manufacture
IL275434B (en) Method for producing thiocarboxamidine salt compound
SG11202101704VA (en) Method of producing piperylene
PT3864118T (en) Method of producing biodiesel
EP3891099C0 (en) Method of preparing phosphorus
SG11202106891PA (en) Method for producing cyclobutene
SG11202100983XA (en) Method of producing tetracyclic compound
GB201809783D0 (en) A method of producing a structure
ZA201808254B (en) Method for producing crystal of uracil compound
HUE065555T2 (en) Method for producing butadiene compound
SG11201907182QA (en) Method for producing perfluoroalkadiene compounds
IL279070A (en) Method for producing diarylpyridine derivatives
SG11202103673UA (en) Method for producing perfluorocycloalkene compound